Overall verdict
Sell
2.9/10
1-year performance
-20.73%
Score breakdown
Down 20.7% over 1 year, 3% of the 52-week range.
Strongest: Growth 8.3/10. Weakest: Shareholder return 0.0/10.
Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 agonist in preclinical studies ; long-acting peptide MC4R agonists ; and Bremelanotide co-administration with Tirzepatide to treat obesity completed Phase 2 clinical trial ;
completed a phase 2 of diabetic nephropathy It also provides pl9643 for dry eye disease ; and oral PL8177 for inflammatory bowel diseases. licensing arrangements and other strategic transactions to advance and maximize the value of certain product candidates and program for the treatment of retinal diseases and with Altanispac Labs for PL9643 for the treatment of dry eye disease ; and oral PL8177 for the treatment inflammatory bowel diseases. Palatin Technologies, Inc. was incorporated in 1986 and is based in Princeton, New Jersey.
Sector
Health Care
Industry
Biotechnology
Primary listing
Lse
United States
CEO
Carl Spana
Founded
1986
Employees
25
Revenue / employee
527 401 USD
Next earnings
November 13, 2026 (estimated)
Institutional holders
- Driehaus Capital Management LLC9.38%
- Jupiter Topco LLC7.87%
- Logos Global Management LP7.31%
- RA CAPITAL MANAGEMENT, L.P.3.49%
- Balyasny Asset Management L.P.2.31%
- MORGAN STANLEY1.53%
- Opaleye Management Inc.1.15%
- GEODE CAPITAL MANAGEMENT, LLC1.09%
- VANGUARD CAPITAL MANAGEMENT LLC1.06%
- Other institutions3.31%
- Rest of the register61.49%
25 13F filings as of June 30, 2026: US managers above $100M, filed up to 45 days after quarter end. No insiders, no retail. A share on loan is declared by its lender and by whoever bought it from the short seller, so the total can exceed 100%.
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
27.71 USD
52-week low
5.75 USD
1-year performance
-20.73%
Declining
Year-to-date performance
-62.97%
Declining
Drawdown
-76.54%
Major drawdown
Position in the 52-week range
3% of range
Gross margin 99.3%, the company loses 63.5% of its revenue, ROIC -834.1%, ROE -877.5%.
Net margin
-63.54%
Negative
Sector -224.99%|S&P 13.13%
Gross margin
99.26%
Exceptional
Return on equity (ROE)
-877.53%
Negative
Sector -58.37%|S&P 16.52%
Return on invested capital (ROIC)
-834.12%
Negative
Free cash flow margin (FCF)
-103.03%
Negative
Revenue to net income
Growth
8.3/10Revenue (trailing 12 months)
13.2M USD
Revenue growth (1y)
—
Revenue growth (3y)
171.65%
Hyper-growth
EPS growth (1y)
—
EPS CAGR (5y)
—
EPS revisions (3 months)
—
Valuation
0.0/10The company loses money, so no valuation multiple can be read: a negative P/E is not a discount.
P/E (TTM)
—
N/A (loss)
Sector 11.8x|S&P 23.7x
Forward P/E (adjusted)
—
N/A (loss)
EV / EBITDA
—
N/A (loss)
Sector 15.4x|S&P 15.0x
PEG
—
Sector 1.07|S&P 0.89
Market cap
11.6M USD
Financial strength
5.8/10Cash covers 3349.4% of the debt, no net debt (net cash).
Net debt / EBITDA
—
Gearing (net debt / equity)
-108.70%
Net cash
Cash
7.5M USD
Cash / market cap
64.82%
Very solid
Cash / total debt
3349.45%
Net cash
Interest coverage
-1288.8x
Stretched
Net debt
-7.3M USD
Equity
6.7M USD
Closed daily candles, 2 years
Last close on October 14, 2026: 7.65 USD
- MM209.87
- MM509.86
- MM20013.06
- RSI 1436.0
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
+1.70%
200-day average slope, 3 months
-28.33%
50-day average slope, 1 month
-7.08%
Price structure
Lower lows
Bullish RSI divergence
No
20-day volatility
6.94 % per day
Volatility change
-8.13%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2027 | -2.18 (3) | -2.41 (2) | 9 (3) | — | -14 (2) |
Amounts in millions of USD, EPS in USD per share. In brackets, the number of analysts. Consensus as of September 30, 2026.
Same sub-industry: 780 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ARTV | 6.2 | N/A | 296M USD | Not meaningful (loss) | -36183.7 % | -100.0 % | -35.4 % | 3.6x | -26.0 % | 108.2 % | ||
| 2 | SRZN | 5.5 | 4.3 | 295M USD | Not meaningful (loss) | -3042.9 % | 408.6 % | — | 2.2x | -11.9 % | 83.8 % | ||
| 3 | ANIK | 4.6 | 3.7 | 277M USD | Not meaningful (loss) | -2.6 % | 15.6 % | -1.9 % | -25.9x | 0.2 % | 125.1 % | ||
| 4 | ALERS | 4.6 | 4.8 | 278M USD | 35.3x | 4.2 % | 9.1 % | 3.7 % | -0.1x | 2.1 % | -0.2 % | ||
| 5 | BNTC | 4.4 | N/A | 295M USD | Not meaningful (loss) | — | — | -33.1 % | 3.5x | -5.9 % | -43.9 % | ||
| 6 | A475830 | 3.2 | 3.3 | 258M USD | 19.4x | 45646.4 % | 479.1 % | 9.5 % | 2.5x | -13.1 % | -50.8 % | ||
| 7 | 0KF3 | 2.9 | 2.5 | 11.6M USD | Not meaningful (loss) | -63.5 % | — | -834.1 % | — | -117.5 % | -20.7 % | ||
| 8 | A376900 | 2.8 | 3.1 | 262M USD | Not meaningful (loss) | -38.7 % | 36.6 % | -161.2 % | -7.1x | -6.4 % | -27.2 % | ||
| 9 | 4169 | 1.4 | 1.4 | 296M USD | Not meaningful (loss) | -4.5 % | 10.0 % | — | -11.9x | — | -1.0 % |
